AAPL347.10+3.19 (+0.93%) ▲|ABBV286.39-0.35 (-0.12%) ▼|ABT103.10-1.78 (-1.70%) ▼|ACN235.16-12.07 (-4.88%) ▼|ADBE248.36-10.26 (-3.97%) ▼|AMAT395.93+8.34 (+2.15%) ▲|AMD560.26+28.98 (+5.45%) ▲|AMGN447.95+3.32 (+0.75%) ▲|AMT183.83-4.45 (-2.36%) ▼|AMZN253.10+4.01 (+1.61%) ▲|AVGO342.33+13.16 (+4.00%) ▲|AXP312.91-2.14 (-0.68%) ▼|BA168.18-20.13 (-10.69%) ▼|BAC50.68+0.16 (+0.32%) ▲|BKNG150.14-3.00 (-1.96%) ▼|BLK1,136.05+8.39 (+0.74%) ▲|BMY61.55-0.06 (-0.10%) ▼|BNY147.58+0.40 (+0.27%) ▲|BRK-B542.99-5.57 (-1.02%) ▼|C122.69+1.65 (+1.36%) ▲|CAT713.31+21.18 (+3.06%) ▲|CL92.17-0.93 (-1.00%) ▼|CMCSA21.84-0.21 (-0.95%) ▼|COF203.44+1.09 (+0.54%) ▲|COP147.96-3.41 (-2.25%) ▼|COST992.13-13.03 (-1.30%) ▼|CRM240.89-6.72 (-2.71%) ▼|CSCO111.38+1.14 (+1.03%) ▲|CVS91.13-1.40 (-1.51%) ▼|CVX228.23-3.78 (-1.63%) ▼|DE639.58-1.67 (-0.26%) ▼|DHR232.00-0.97 (-0.42%) ▼|DIS110.23-0.17 (-0.15%) ▼|DUK124.80+0.36 (+0.29%) ▲|EMR166.27+4.57 (+2.83%) ▲|FDX307.10+6.52 (+2.17%) ▲|GD354.89-2.15 (-0.60%) ▼|GE297.66+9.23 (+3.20%) ▲|GEV895.08+40.46 (+4.73%) ▲|GILD159.08+0.39 (+0.25%) ▲|GM80.54+4.23 (+5.54%) ▲|GOOG316.83+2.64 (+0.84%) ▲|GOOGL320.58+3.78 (+1.19%) ▲|GS911.77+18.49 (+2.07%) ▲|HD318.50-0.88 (-0.28%) ▼|HON218.81-0.47 (-0.21%) ▼|IBM250.25-3.19 (-1.26%) ▼|INTC93.74+3.27 (+3.61%) ▲|INTU328.45-11.44 (-3.37%) ▼|ISRG445.88-5.75 (-1.27%) ▼|JNJ268.73+2.43 (+0.91%) ▲|JPM335.79+1.75 (+0.52%) ▲|KO91.18-1.52 (-1.64%) ▼|LIN508.65+1.09 (+0.21%) ▲|LLY1,281.91+2.77 (+0.22%) ▲|LMT622.99-12.21 (-1.92%) ▼|LOW198.18-0.04 (-0.02%) ▼|LRCX240.85+3.35 (+1.41%) ▲|MA609.85-3.65 (-0.59%) ▼|MCD249.47-1.36 (-0.54%) ▼|MDLZ62.35-0.62 (-0.98%) ▼|MDT93.95-0.84 (-0.89%) ▼|META620.19-10.37 (-1.64%) ▼|MMM171.58-1.21 (-0.70%) ▼|MO73.49-0.13 (-0.18%) ▼|MRK141.82+1.21 (+0.86%) ▲|MS186.91+3.42 (+1.86%) ▲|MSFT531.33-1.27 (-0.24%) ▼|MU928.76+25.06 (+2.77%) ▲|NEE82.42+0.38 (+0.46%) ▲|NFLX62.52-1.38 (-2.16%) ▼|NKE37.56-0.35 (-0.92%) ▼|NOW154.78-3.40 (-2.15%) ▼|NVDA217.94+1.94 (+0.90%) ▲|ORCL130.53+4.47 (+3.55%) ▲|PEP133.50-1.96 (-1.45%) ▼|PFE29.80+0.01 (+0.03%) ▲|PG159.23-0.69 (-0.43%) ▼|PLTR198.73-0.11 (-0.06%) ▼|PM202.62+0.75 (+0.37%) ▲|QCOM184.17+4.57 (+2.54%) ▲|RTX194.60-2.88 (-1.46%) ▼|SBUX103.04+0.35 (+0.34%) ▲|SCHW89.30-0.43 (-0.48%) ▼|SO92.65+0.08 (+0.09%) ▲|SPG212.28-0.41 (-0.19%) ▼|T20.94+0.09 (+0.43%) ▲|TMO693.02+8.13 (+1.19%) ▲|TMUS146.83-0.10 (-0.07%) ▼|TSLA407.46+15.84 (+4.04%) ▲|TXN308.91+10.79 (+3.62%) ▲|UBER65.78-0.35 (-0.53%) ▼|UNH410.39-0.31 (-0.08%) ▼|UNP299.88+2.91 (+0.98%) ▲|UPS106.09+5.77 (+5.75%) ▲|USB59.74+0.04 (+0.07%) ▲|V401.86-2.30 (-0.57%) ▼|VZ43.93+0.83 (+1.93%) ▲|WFC82.66+0.01 (+0.01%) ▲|WMT119.32-0.97 (-0.81%) ▼|XOM179.91-4.63 (-2.51%) ▼|AAPL347.10+3.19 (+0.93%) ▲|ABBV286.39-0.35 (-0.12%) ▼|ABT103.10-1.78 (-1.70%) ▼|ACN235.16-12.07 (-4.88%) ▼|ADBE248.36-10.26 (-3.97%) ▼|AMAT395.93+8.34 (+2.15%) ▲|AMD560.26+28.98 (+5.45%) ▲|AMGN447.95+3.32 (+0.75%) ▲|AMT183.83-4.45 (-2.36%) ▼|AMZN253.10+4.01 (+1.61%) ▲|AVGO342.33+13.16 (+4.00%) ▲|AXP312.91-2.14 (-0.68%) ▼|BA168.18-20.13 (-10.69%) ▼|BAC50.68+0.16 (+0.32%) ▲|BKNG150.14-3.00 (-1.96%) ▼|BLK1,136.05+8.39 (+0.74%) ▲|BMY61.55-0.06 (-0.10%) ▼|BNY147.58+0.40 (+0.27%) ▲|BRK-B542.99-5.57 (-1.02%) ▼|C122.69+1.65 (+1.36%) ▲|CAT713.31+21.18 (+3.06%) ▲|CL92.17-0.93 (-1.00%) ▼|CMCSA21.84-0.21 (-0.95%) ▼|COF203.44+1.09 (+0.54%) ▲|COP147.96-3.41 (-2.25%) ▼|COST992.13-13.03 (-1.30%) ▼|CRM240.89-6.72 (-2.71%) ▼|CSCO111.38+1.14 (+1.03%) ▲|CVS91.13-1.40 (-1.51%) ▼|CVX228.23-3.78 (-1.63%) ▼|DE639.58-1.67 (-0.26%) ▼|DHR232.00-0.97 (-0.42%) ▼|DIS110.23-0.17 (-0.15%) ▼|DUK124.80+0.36 (+0.29%) ▲|EMR166.27+4.57 (+2.83%) ▲|FDX307.10+6.52 (+2.17%) ▲|GD354.89-2.15 (-0.60%) ▼|GE297.66+9.23 (+3.20%) ▲|GEV895.08+40.46 (+4.73%) ▲|GILD159.08+0.39 (+0.25%) ▲|GM80.54+4.23 (+5.54%) ▲|GOOG316.83+2.64 (+0.84%) ▲|GOOGL320.58+3.78 (+1.19%) ▲|GS911.77+18.49 (+2.07%) ▲|HD318.50-0.88 (-0.28%) ▼|HON218.81-0.47 (-0.21%) ▼|IBM250.25-3.19 (-1.26%) ▼|INTC93.74+3.27 (+3.61%) ▲|INTU328.45-11.44 (-3.37%) ▼|ISRG445.88-5.75 (-1.27%) ▼|JNJ268.73+2.43 (+0.91%) ▲|JPM335.79+1.75 (+0.52%) ▲|KO91.18-1.52 (-1.64%) ▼|LIN508.65+1.09 (+0.21%) ▲|LLY1,281.91+2.77 (+0.22%) ▲|LMT622.99-12.21 (-1.92%) ▼|LOW198.18-0.04 (-0.02%) ▼|LRCX240.85+3.35 (+1.41%) ▲|MA609.85-3.65 (-0.59%) ▼|MCD249.47-1.36 (-0.54%) ▼|MDLZ62.35-0.62 (-0.98%) ▼|MDT93.95-0.84 (-0.89%) ▼|META620.19-10.37 (-1.64%) ▼|MMM171.58-1.21 (-0.70%) ▼|MO73.49-0.13 (-0.18%) ▼|MRK141.82+1.21 (+0.86%) ▲|MS186.91+3.42 (+1.86%) ▲|MSFT531.33-1.27 (-0.24%) ▼|MU928.76+25.06 (+2.77%) ▲|NEE82.42+0.38 (+0.46%) ▲|NFLX62.52-1.38 (-2.16%) ▼|NKE37.56-0.35 (-0.92%) ▼|NOW154.78-3.40 (-2.15%) ▼|NVDA217.94+1.94 (+0.90%) ▲|ORCL130.53+4.47 (+3.55%) ▲|PEP133.50-1.96 (-1.45%) ▼|PFE29.80+0.01 (+0.03%) ▲|PG159.23-0.69 (-0.43%) ▼|PLTR198.73-0.11 (-0.06%) ▼|PM202.62+0.75 (+0.37%) ▲|QCOM184.17+4.57 (+2.54%) ▲|RTX194.60-2.88 (-1.46%) ▼|SBUX103.04+0.35 (+0.34%) ▲|SCHW89.30-0.43 (-0.48%) ▼|SO92.65+0.08 (+0.09%) ▲|SPG212.28-0.41 (-0.19%) ▼|T20.94+0.09 (+0.43%) ▲|TMO693.02+8.13 (+1.19%) ▲|TMUS146.83-0.10 (-0.07%) ▼|TSLA407.46+15.84 (+4.04%) ▲|TXN308.91+10.79 (+3.62%) ▲|UBER65.78-0.35 (-0.53%) ▼|UNH410.39-0.31 (-0.08%) ▼|UNP299.88+2.91 (+0.98%) ▲|UPS106.09+5.77 (+5.75%) ▲|USB59.74+0.04 (+0.07%) ▲|V401.86-2.30 (-0.57%) ▼|VZ43.93+0.83 (+1.93%) ▲|WFC82.66+0.01 (+0.01%) ▲|WMT119.32-0.97 (-0.81%) ▼|XOM179.91-4.63 (-2.51%) ▼|
11.8 C
New York
Wednesday, October 28, 2026

Tag: infections

newsFORsourcecompanycontentinformation1releasesmarket

CD40/CD40L Inhibitors Market on Growth Trajectory Driven by Advancements in Autoimmune and Cancer Therapeutics | DelveInsight

The CD40/CD40L inhibitors market is experiencing steady growth driven by increasing research into autoimmune diseases, organ transplantation, and cancer immunotherapy. The rising prevalence of...

Aicuris Enrolled Last Participant in Pivotal Trial with Pritelivir to Treat Refractory Herpes Simplex Infection in Immunocompromised Patients

Wuppertal, Germany, July 24, 2025 - Aicuris Anti-infective Cures AG today announced the completion of patient enrollment in its pivotal Phase 3 trial, PRIOH-1, evaluating pritelivir for the treatment of refractory and/or treatment resistant herpes simplex virus (HSV) infections in immunocompromised patients. The company’s lead candidate is a small molecule specifically inhibiting the viral helicase-primase complex, which represents a novel mechanism of action distinct from current HSV therapies.

Local Plastic Surgeon in Paramus New Jersey, Dr. Andrew Nouri Educates Patients on Insurance Coverage for Medically Necessary Breast Reduction

Paramus, NJ, July 23, 2025 (GLOBE NEWSWIRE) -- For many women, large breasts are not just a cosmetic concern, they’re a medical one. Chronic back, neck, and shoulder pain, rashes under the breasts, painful grooves from bra straps, posture problems, and even emotional distress are just some of the symptoms that can come with disproportionately large breasts.

XORTX Completes Non-Brokered Private Placement of Units

Not For Distribution to United States News Wire Services or for Dissemination in the United States

Llusern Scientific Announces Key Appointments to Strengthen its Executive Team

CTO, CMO and CFO appointments to advance the commercial launch of its precision point-of-care diagnostic Lodestar DX for UTIs worldwide 
CTO, CMO and CFO appointments to advance the commercial launch of its precision point-of-care diagnostic Lodestar DX for UTIs worldwide

Public health notice: Outbreak of Salmonella infections linked to various brands of salami and cacciatore products

July 19, 2025: Update This outbreak investigation is ongoing. The public health notice will be updated as the investigation evolves. OTTAWA, ON, July 19, 2025 /CNW/...

Total Investment of Approx. USD 7.3 Million in Malaria and TB R&D Projects With Partners Including European Vaccine Initiative, University of Copenhagen, and University...

TOKYO, July 17, 2025 /PRNewswire/ -- The Global Health Innovative Technology (GHIT) Fund announced today a total investment of approximately JPY 1 billion (USD 7.3...

Quetzal Therapeutics Debuts with Expert Leadership, High-Impact Pipeline and $50 Million of Committed Capital

Quetzal Therapeutics, a newly formed biopharmaceutical company, announced its official launch today with $50 million of committed capital.

ArkBio’s Ziresovir Included into Pediatric RSV Drug Priority List by WHO

SHANGHAI, July 16, 2025 /PRNewswire/ -- In the newly released "Paediatric drug optimization for respiratory syncytial virus (PADO-RSV) meeting report" by Global Accelerator for...

ArkBio’s Ziresovir Included into Pediatric RSV Drug Priority List by WHO

SHANGHAI, July 16, 2025 /PRNewswire/ -- In the newly released "Paediatric drug optimization for respiratory syncytial virus (PADO-RSV) meeting report" by Global Accelerator for...

ArkBio’s Ziresovir Included into Pediatric RSV Drug Priority List by WHO

SHANGHAI, July 15, 2025 /PRNewswire/ -- In the newly released "Paediatric drug optimization for respiratory syncytial virus (PADO-RSV) meeting report" by Global Accelerator for...

PHASE Scientific Expands INDICAID® Respiratory Portfolio with Exclusive U.S. Launch of Novel FebriDx® Test

FebriDx® is a first-in-class rapid test that differentiates between bacterial and non-bacterial respiratory infections, offering significant potential to address critical unmet needs in patient...

Public health notice: Outbreak of Salmonella infections linked to Rea brand and Bona brand salami products

July 15, 2025: Update OTTAWA, ON, July 15, 2025 /CNW/ - At a glance Do not consume, use, sell, serve or distribute recalled: Rea brand Genoa Salami Sweet (Lots: 5035...

RESEARCH SHOWS EARLY CANCER CELLS CAN BE RAPIDLY DETECTED THROUGH ELECTRONIC SEMICONDUCTORS

CLEVELAND, July 15, 2025 /PRNewswire/ -- IdentifySensors Biologics, a leader in digital diagnostic technologies, has demonstrated that its electronic biosensors used to detect pathogens...

- A word from our sponsors -

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsInfections

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers